Clinigen Group PLC (LON:CLIN) chief executive Shaun Chilton discusses the group's half year trading update with Proactive's Andrew Scott.
Chilton says they're well positioned for another year of growth with trading at the halfway stage in line with expectations.
Revenues were up 28% year-on-year, although the figure was distorted by what are called 'pass through costs' associated with the unlicensed medicines it accesses on behalf of patients in need.
Meet Netscientific PLC, discoverIE Group plc, Itaconix Plc and Realm Therapeutics plc at our event, London, 25 January 2018.Register here >>